Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicago Inc MDCGF

GREY:MDCGF - Post Discussion

Medicago Inc > vrai ou faux?
View:
Post by delooutchie on Feb 04, 2011 7:45pm

vrai ou faux?




JANTA


I talked with IR this afternoon. Results of phase2 (H5N1) will be coming out as schedule at the end of the month. The exciting news for me is the fact that a phase 3 is not necessary ( I always thought it was for this particular vaccine). They will apply for a “production” permit which can be (has to be) renewed every 18 months. Other vaccines will be developed and tested in 2011 and 2012. This year, they intend to issue a press release at least every two months to keep investors well informed. They are very excited concerning the prospect of the company. NO PP IS BEING PLANNED. Apparently Paradigm Capital did not lower its $2.00 plus target...their deadline is.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities